| Business Summary | | Array
BioPharma,
Inc.
(Array)
is
a
discovery
research
company
creating
drug
candidates
through
innovations
in
chemistry.
The
Company's
experienced
scientists
provide
products
and
services
to
create,
evaluate
and
optimize
potential
drug
candidates
in
collaboration
with
pharmaceutical
and
biotechnology
companies.
Array
believes
its
information-based
approach
improves
the
efficiency
of
the
drug
discovery
process
and
increases
the
quality
of
potential
drug
candidates.
The
Company
also
applies
these
capabilities
internally
for
its
own
drug
discovery
programs.
Array
provides
a
broad
range
of
drug
discovery
products
and
services,
including:
optimer
building
blocks;
lead
generation;
lead
optimization;
and
process
research
and
development.
The
Company
offers
products
and
services
to
collaborators
across
the
drug
discovery
process.
The
Company's
proprietary
chemoinformatics
platform
supports
the
entire
drug
discovery
process. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Array
BioPharma
is
a
discovery
research
company
creating
drug
candidates
through
innovations
in
chemistry
by
providing
products
and
services
in
collaboration
with
pharmaceutical
companies.
For
the
nine
months
ended
3/31/01,
revenues
totalled
$11.3
million,
up
from
$4.5
million.
Net
loss
applicable
to
Common
totalled
$14
million,
up
from
$3.3
million.
Results
reflect
increased
sales
of
the
Company's
lead
optimization
services,
offset
by
increased
staffing
levels. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
5,671;
after
tax
earnings
were
-1,381. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY1999
Compensation | | Pay | Exer | |
| Kyle Lefkoff, 41 Chairman | -- | -- | Robert Conway, 46 CEO,
Director | $280K | -- | Kevin Koch, Ph.D, 40 Pres,
Director and CSO | 160K | $78K | Michael Carruthers, 42 CFO,
Sec. | 112K | 370K | David Snitman, Ph.D, 48 COO,
VP-Bus. Devel., Director | 160K | -- | Dollar
amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|